Celldex Therapeutics Presents Positive Data from
- Data updates at EAACI 2023 continue to position barzolvolimab as a potential best-in-class addition to a historically limited treatment landscape -- At...
Source: globenewswire.com
Page 9 - Complete Response News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Complete Response. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Complete Response Today - Breaking & Trending Today
Johnson & Johnson : Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma
News Release Media Contact: Christie Corbett +1 857-636-0211 Satu Glawe +49 172-294-6264 ... | June 5, 2023
Source: marketscreener.com
Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023
Real-World Results Demonstrate Objective Response Rate of 67% in 24 EBV+ PTLD Patients 91% Overall Survival at One Year for Patients Responding to Tab-cel Compared to 34% for... | June 5, 2023
Source: marketscreener.com
ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer
/PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced the latest clinical...
Source: prnewswire.com
ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer
YANTAI, China, June 5, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced the latest clinical research results on disitamab vedotin (RC48) at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023, in Chicago. Researchers tested disitamab vedotin and toripalimab in combination on...
Source: asiaone.com